Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.11)
# 2,672
Out of 4,784 analysts
59
Total ratings
36.84%
Success rate
-2.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Hold | $74 → $72 | $60.60 | +18.81% | 9 | Mar 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $48.88 | +55.48% | 2 | Mar 11, 2025 | |
| BIIB Biogen | Maintains: Buy | $220 → $210 | $138.37 | +51.77% | 3 | Feb 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $822.51 | +26.20% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $205.29 | +5.70% | 3 | Feb 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,126 → $1,004 | $637.36 | +57.52% | 5 | Jan 8, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $100 → $43 | $10.79 | +298.52% | 4 | Dec 23, 2024 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $25.21 | +26.93% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $23.27 | +114.87% | 6 | Nov 27, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $36 → $45 | $32.84 | +37.03% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $29.62 | +78.93% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $2.30 | +2,247.83% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.19 | +142.33% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $12.15 | +196.30% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $43.19 | +62.07% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $0.78 | +7,581.47% | 2 | Aug 11, 2023 |
Incyte
Mar 18, 2025
Maintains: Hold
Price Target: $74 → $72
Current: $60.60
Upside: +18.81%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $48.88
Upside: +55.48%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $220 → $210
Current: $138.37
Upside: +51.77%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $822.51
Upside: +26.20%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $205.29
Upside: +5.70%
Regeneron Pharmaceuticals
Jan 8, 2025
Maintains: Buy
Price Target: $1,126 → $1,004
Current: $637.36
Upside: +57.52%
Keros Therapeutics
Dec 23, 2024
Maintains: Buy
Price Target: $100 → $43
Current: $10.79
Upside: +298.52%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.21
Upside: +26.93%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $23.27
Upside: +114.87%
Scholar Rock Holding
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $32.84
Upside: +37.03%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $29.62
Upside: +78.93%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $2.30
Upside: +2,247.83%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $6.19
Upside: +142.33%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $12.15
Upside: +196.30%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $43.19
Upside: +62.07%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $0.78
Upside: +7,581.47%